Pricing Log in Create free account
Saturday 17 October 2026 Export IART’s income statement to Excel — free account

Integra LifeSciences Holdings Corporation

IART Healthcare Medical Devices

Integra LifeSciences Holdings Corporation’s revenue for fiscal 2025 (year ended December 2025) was $1.6 billion, up 1.53% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 101.0%, free cash flow grew 193.5% and total debt rose 1.51%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

13.21 0.32 −2.37%
Market cap
$1.1B
P/E
0.0×
Fwd P/E
26.1×
Dividend yield
—
F-score
5/9
Altman Z
0.62
Beneish M
−3.25
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.10
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy 1 — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 13.89%

Capital & Financial Ratios $m

Market Cap 1,050.00
Revenue 1,647.67
Net Income (7.24)
Free Cash Flow 25.80
Net Debt 1,554.62
Current Ratio 3.60 (at or above 1.5: strong)
Debt/Equity 1.75
P/E ratio 0.00
Fwd P/E 26.10
P/S ratio 0.62
P/B ratio 0.98
Past 5Y EPS Growth —
This Y EPS Growth 8.11%
Next Y EPS Growth 5.54%
Next Y revenue growth 1.27%
Next 5Y EPS Growth 7.54%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.6×, against a ten-year median of 3.7×; over the ten years it ranged from 1.4× in 2026 to 5.4× in 2021.
P/S against its own 10 years 6.49%
10-year low 10-year high
P/B against its own 10 years 9.03%
10-year low 10-year high
EV/Sales against its own 10 years 6.08%
10-year low 10-year high
EV/FCF against its own 10 years 92.08%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 309 274 264 274
Receivables 259 272 279 267
Inventory 390 429 493 492
Other 33 30 28 54
1,058 1,082 1,160 1,191
2023 2024 2025 Q'26
Payables 92 83 96 83
ST’ Debt — 573 88 —
Other 9 10 11 12
307 922 456 331

Compound Annual Growth %

10y 5y 3y
Sales 6.36% 3.57% 1.63%
Cash Flow (7.07%) (24.39%) (42.46%)
Earnings 0.00% 0.00% 0.00%
Book Value 3.34% (7.18%) (16.69%)

Revenue $m

Mar Jun Sep Dec Year
’26 392 419 — — —
’25 383 416 402 435 1,635
’24 369 418 381 443 1,611
’23 381 381 382 397 1,542
’22 377 398 385 398 1,558
’21 360 390 387 406 1,542
’20 354 259 370 389 1,372
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 10 23 — — —
’25 (11) 9 41 12 50
’24 16 40 22 51 129
’23 26 28 27 59 140
’22 44 66 68 85 264
’21 69 91 83 69 312
’20 21 33 70 80 204
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (5) 10 — — —
’25 (40) (11) 26 (5) (45)
’24 0 11 (7) 21 15
’23 12 13 14 34 73
’22 35 57 59 82 233
’21 62 85 75 42 264
’20 4 29 63 72 169
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.06) 0.06 — — —
’25 (0.33) (6.31) (0.07) (0.02) (6.74)
’24 (0.04) (0.16) (0.14) 0.25 (0.09)
’23 0.29 0.05 0.24 0.25 0.84
’22 0.39 0.54 0.60 0.63 2.16
’21 0.53 0.41 0.51 0.53 1.98
’20 0.11 0.00 0.38 1.09 1.57
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.8
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 27.38 40.51 42.33 42.14 34.21 61.85 40.67 33.44 16.81 10.87

Analyst estimates 2026–2028

Powerpack
High 44.43 56.42 67.50 65.09 67.29 77.40 69.90 60.69 45.42 27.13
People
People Employees 3,700 4,400 4,500 4,000 3,700 3,800 3,722 3,946 4,396 4,427
Revenue/emp, $m 0.27 0.27 0.33 0.38 0.37 0.41 0.42 0.39 0.37 0.37
Income, $m
Income, $m Revenue 992 1,188 1,472 1,518 1,372 1,542 1,558 1,542 1,611 1,635
Gross margin, % 64.81 63.35 61.19 62.79 62.03 61.24 62.29 57.39 54.77 50.86
EBT 90 11 57 60 94 215 214 81 (18) (564)
EBT margin, % 9.11 0.96 3.90 3.96 6.82 13.92 13.73 5.26 (1.13) (34.46)
Net income 75 65 61 50 134 169 181 68 (7) (516)
Depreciation 75 92 117 115 144 127 125 130 146 157
Per share, $
Per share, $ Revenue 13.34 15.45 17.77 17.72 16.21 18.21 18.77 19.25 20.91 21.33
Earnings 0.94 0.82 0.72 0.58 1.57 1.98 2.16 0.84 (0.09) (6.74)
Cash flow 1.56 1.49 2.41 2.70 2.41 3.69 3.19 1.75 1.68 0.66
Capex (0.63) (0.56) (0.93) (0.81) (0.42) (0.57) (0.38) (0.83) (1.49) (1.25)
Free cash flow 0.93 0.93 1.48 1.89 1.99 3.12 2.81 0.91 0.19 (0.59)
Book value 11.29 12.51 16.60 16.54 17.90 19.89 21.74 19.83 20.07 13.61
Shares, m 74 77 83 86 85 85 83 80 77 77
Valuation, ×
Valuation, × P/E 46.55 57.16 62.64 100.48 41.20 33.83 25.79 52.11 0.00 0.00
P/S 3.19 3.03 2.54 3.29 4.01 3.68 2.97 2.25 1.08 0.58
P/B 3.77 3.75 2.72 3.52 3.63 3.37 2.56 2.18 1.13 0.91
EV/Sales 3.76 4.40 3.35 4.05 4.77 4.36 3.61 3.06 2.01 1.53
EV/FCF 53.81 73.22 40.32 37.99 38.83 25.42 24.11 64.52 129.88 (80.70)
Cash, $m
Cash, $m Operating cash flow 116 115 200 231 204 312 264 140 129 50
Capex (47) (43) (77) (69) (35) (48) (31) (67) (114) (96)
Free cash flow 69 71 122 162 169 264 233 73 15 (45)
Balance, $m
Balance, $m Working capital 372 473 513 527 836 814 841 751 160 704
Total debt 665 1,841 1,355 1,360 1,521 1,561 1,458 1,485 1,769 1,817
Net debt 563 1,666 1,216 1,161 1,051 1,048 1,002 1,176 1,496 1,554
Shareholders’ equity 840 962 1,376 1,417 1,515 1,685 1,804 1,588 1,545 1,043
Returns, %
Returns, % ROA 4.16 2.58 1.92 1.57 3.87 4.57 4.71 1.77 (0.18) (13.52)
ROIC 5.14 1.07 2.68 2.27 3.69 4.51 5.32 2.52 0.58 (11.87)
ROE 9.37 7.19 5.20 3.60 9.13 10.57 10.35 3.99 (0.44) (39.90)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Integra LifeSciences Holdings Corporation vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
TNDM Tandem Diabetes Care, Inc. $1.2B — (loss-making) — (loss-making) +5.77% (above 0%: growing) n/m −146.34% (below 0%: shrinking) 56.87% (5.42%) Compare
IRMD iRadimed Corporation $1.1B 48.5× 48.7× +0.28% (above 0%: growing) −8.89% (below 0%: shrinking) +11.66% (above 0%: growing) 74.07% 31.23% Compare
ENOV Enovis Corporation $1.1B — (loss-making) 195× +3.23% (above 0%: growing) n/m +815.79% (above 0%: growing) 61.64% 2.99% Compare
AORT Artivion, Inc. $1.1B — (loss-making) 142× +11.32% (above 0%: growing) n/m −202.47% (below 0%: shrinking) 64.03% (6.65%) Compare
CBLL CeriBell, Inc. $1.1B — (loss-making) — (loss-making) +32.54% (above 0%: growing) n/m −68.63% (below 0%: shrinking) 92.32% (71.11%) Compare
IART Integra LifeSciences Holdings Corporation $1.1B — (loss-making) 26.1× +0.76% (above 0%: growing) n/m +193.48% (above 0%: growing) 52.47% 4.61%
LMRI Lumexa Imaging Holdings, Inc. $1.0B — (loss-making) 14.2× +7.82% (above 0%: growing) n/m +257.54% (above 0%: growing) 14.72% 8.72% Compare
PRCT PROCEPT BioRobotics Corporation $1.0B — (loss-making) — (loss-making) +19.34% (above 0%: growing) n/m −24.43% (below 0%: shrinking) 66.01% (28.98%) Compare
QDEL QuidelOrtho Corporation $953.9M — (loss-making) — (loss-making) +2.77% (above 0%: growing) n/m −61.45% (below 0%: shrinking) 43.26% (3.46%) Compare
Median of peers $1.1B — 95.4× +6.80% — −42.94% 62.84% (4.44%)

All 149 Medical Devices stocks →

Integra LifeSciences Holdings Corporation (IART) key facts

  • Strength: Integra LifeSciences Holdings Corporation’s revenue for fiscal 2025 (year ended December 2025) was $1.6 billion, up 1.53% from fiscal 2024.
  • Integra LifeSciences Holdings Corporation (IART) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, IART traded at $13.21, a market capitalization of $1.1 billion.
  • Return on equity was −39.9% and debt-to-equity 1.75.
  • Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 0.62 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Integra LifeSciences Holdings Corporation (IART) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/IART · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com